152 related articles for article (PubMed ID: 16834573)
1. 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.
Matthews KE; Hermans IF; Roberts JM; Ching LM; Ronchese F
Immunol Cell Biol; 2006 Aug; 84(4):383-9. PubMed ID: 16834573
[TBL] [Abstract][Full Text] [Related]
2. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
3. Using macrophage activation to augment immunotherapy of established tumours.
Fridlender ZG; Jassar A; Mishalian I; Wang LC; Kapoor V; Cheng G; Sun J; Singhal S; Levy L; Albelda SM
Br J Cancer; 2013 Apr; 108(6):1288-97. PubMed ID: 23481183
[TBL] [Abstract][Full Text] [Related]
4. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
5. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
Wallace A; LaRosa DF; Kapoor V; Sun J; Cheng G; Jassar A; Blouin A; Ching LM; Albelda SM
Cancer Res; 2007 Jul; 67(14):7011-9. PubMed ID: 17638914
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
7. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
[TBL] [Abstract][Full Text] [Related]
8. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Browne WL; Wilson WR; Baguley BC; Ching LM
Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
[TBL] [Abstract][Full Text] [Related]
9. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Chung F; Liu J; Ching LM; Baguley BC
Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
[TBL] [Abstract][Full Text] [Related]
10. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
Wu Q; Quan H; Xu Y; Li Y; Hu Y; Lou L
J Pharmacol Exp Ther; 2012 Jun; 341(3):709-17. PubMed ID: 22414857
[TBL] [Abstract][Full Text] [Related]
11. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM
Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
[TBL] [Abstract][Full Text] [Related]
12. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
13. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
[TBL] [Abstract][Full Text] [Related]
14. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
[TBL] [Abstract][Full Text] [Related]
15. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
16. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR
Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
[TBL] [Abstract][Full Text] [Related]
17. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Chung F; Wang LC; Kestell P; Baguley BC; Ching LM
Cancer Chemother Pharmacol; 2004 May; 53(5):377-83. PubMed ID: 15060740
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
[TBL] [Abstract][Full Text] [Related]
19. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
[TBL] [Abstract][Full Text] [Related]
20. IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Roberts ZJ; Ching LM; Vogel SN
J Interferon Cytokine Res; 2008 Mar; 28(3):133-9. PubMed ID: 18338946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
